252 related articles for article (PubMed ID: 27098006)
1. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
Rollison DE; Shain KH; Lee JH; Hampras SS; Fulp W; Fisher K; Al Ali NH; Padron E; Lancet J; Xu Q; Olesnyckyj M; Kenvin L; Knight R; Dalton W; List A; Komrokji RS
Cancer Med; 2016 Jul; 5(7):1694-701. PubMed ID: 27098006
[TBL] [Abstract][Full Text] [Related]
2. Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005.
Kaplan HG; Malmgren JA; Atwood MK
BMC Cancer; 2011 Jun; 11():260. PubMed ID: 21693006
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
Kuendgen A; Lauseker M; List AF; Fenaux P; Giagounidis AA; Brandenburg NA; Backstrom J; Glasmacher A; Hasford J; Germing U;
Leukemia; 2013 Apr; 27(5):1072-9. PubMed ID: 23257782
[TBL] [Abstract][Full Text] [Related]
4. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Attar EC; Amrein PC; Fraser JW; Fathi AT; McAfee S; Wadleigh M; Deangelo DJ; Steensma DP; Stone RM; Foster J; Neuberg D; Ballen KK
Leuk Res; 2013 Sep; 37(9):1016-20. PubMed ID: 23773898
[TBL] [Abstract][Full Text] [Related]
6. Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.
Calip GS; Moran KM; Sweiss KI; Patel PR; Wu Z; Adimadhyam S; Lee TA; Ko NY; Quigley JG; Chiu BC
Cancer; 2019 Apr; 125(7):1143-1154. PubMed ID: 30548485
[TBL] [Abstract][Full Text] [Related]
7. Risk of myelodysplastic syndrome and acute myeloid leukemia post radiation treatment for breast cancer: a population-based study.
Kaplan H; Malmgren J; De Roos AJ
Breast Cancer Res Treat; 2013 Feb; 137(3):863-7. PubMed ID: 23274844
[TBL] [Abstract][Full Text] [Related]
8. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.
Bello C; Yu D; Komrokji RS; Zhu W; Wetzstein GA; List AF; Lancet JE
Cancer; 2011 Apr; 117(7):1463-9. PubMed ID: 21425147
[TBL] [Abstract][Full Text] [Related]
9. Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma.
Jonsdottir G; Björkholm M; Turesson I; Hultcrantz M; Diamond B; Porwit A; Landgren O; Kristinsson SY
Eur J Haematol; 2021 Aug; 107(2):275-282. PubMed ID: 33966293
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.
Chen Y; Kantarjian H; Estrov Z; Faderl S; Ravandi F; Rey K; Cortes J; Borthakur G
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):341-4. PubMed ID: 22579233
[TBL] [Abstract][Full Text] [Related]
11. Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?
Zeidan AM; Gore SD; Komrokji RS
Expert Rev Hematol; 2013 Jun; 6(3):251-4. PubMed ID: 23782079
[TBL] [Abstract][Full Text] [Related]
12. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.
Björkholm M; Derolf AR; Hultcrantz M; Kristinsson SY; Ekstrand C; Goldin LR; Andreasson B; Birgegård G; Linder O; Malm C; Markevärn B; Nilsson L; Samuelsson J; Granath F; Landgren O
J Clin Oncol; 2011 Jun; 29(17):2410-5. PubMed ID: 21537037
[TBL] [Abstract][Full Text] [Related]
13. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors.
Krishnan A; Bhatia S; Slovak ML; Arber DA; Niland JC; Nademanee A; Fung H; Bhatia R; Kashyap A; Molina A; O'Donnell MR; Parker PA; Sniecinski I; Snyder DS; Spielberger R; Stein A; Forman SJ
Blood; 2000 Mar; 95(5):1588-93. PubMed ID: 10688812
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
List A
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
[TBL] [Abstract][Full Text] [Related]
15. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
List AF; Bennett JM; Sekeres MA; Skikne B; Fu T; Shammo JM; Nimer SD; Knight RD; Giagounidis A;
Leukemia; 2014 May; 28(5):1033-40. PubMed ID: 24150217
[TBL] [Abstract][Full Text] [Related]
16. Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience.
Aguilera DG; Vaklavas C; Tsimberidou AM; Wen S; Medeiros LJ; Corey SJ
J Pediatr Hematol Oncol; 2009 Nov; 31(11):803-11. PubMed ID: 19801947
[TBL] [Abstract][Full Text] [Related]
17. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650
[TBL] [Abstract][Full Text] [Related]
18. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.
Darrington DL; Vose JM; Anderson JR; Bierman PJ; Bishop MR; Chan WC; Morris ME; Reed EC; Sanger WG; Tarantolo SR
J Clin Oncol; 1994 Dec; 12(12):2527-34. PubMed ID: 7989926
[TBL] [Abstract][Full Text] [Related]
19. Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies.
Adès L; Le Bras F; Sebert M; Kelaidi C; Lamy T; Dreyfus F; Eclache V; Delaunay J; Bouscary D; Visanica S; Turlure P; Bresler AG; Cabrol MP; Banos A; Blanc M; Vey N; Delmer A; Wattel E; Chevret S; Fenaux P
Haematologica; 2012 Feb; 97(2):213-8. PubMed ID: 21993675
[TBL] [Abstract][Full Text] [Related]
20. Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors.
Kaplan HG; Malmgren JA; Li CI; Calip GS
Breast Cancer Res Treat; 2013 Dec; 142(3):629-36. PubMed ID: 24265034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
